Menu
Search
|

Menu

Close

Search

Close
X

Mesoblast Ltd MESO.OQ (NASDAQ Stock Exchange Global Select Market)

▲
4.25 USD
+0.00 (+0.00%)
As of Feb 15
chart
Previous Close 4.25
Open 4.21
Volume 5,283
3m Avg Volume 12,328
Today’s High 4.31
Today’s Low 4.20
52 Week High 8.74
52 Week Low 3.35
Shares Outstanding (mil) 99.73
Market Capitalization (mil) 412.73
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

VIEW MORE
∨
ADVERTISEMENT

RECOMMENDATION

▼
Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
12
FY18
17
FY17
2
FY16
43
EPS (USD)
FY19
-0.041
FY18
-0.075
FY17
-0.198
FY16
-0.020
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.99
Price to Sales (TTM)
vs sector
14.84
10.11
Price to Book (MRQ)
vs sector
0.77
4.60
Price to Cash Flow (TTM)
vs sector
--
26.60
Total Debt to Equity (MRQ)
vs sector
11.59
16.95
LT Debt to Equity (MRQ)
vs sector
11.59
13.45
Return on Investment (TTM)
vs sector
-7.29
12.72
Return on Equity (TTM)
vs sector
-8.79
13.73

EXECUTIVE LEADERSHIP

Brian Jamieson
Independent Non-Executive Chairman of the Board, Since 2007
Salary: $250,000.00
Bonus: --
Silviu Itescu
Chief Executive Officer, Executive Director, Since 2014
Salary: $1,010,000.00
Bonus: $909,000.00
William Burns
Vice Chairman of the Board, Since 2016
Salary: $175,000.00
Bonus: --
Joshua Muntner
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Eric Strati
Senior Vice President - Commercial, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

L 38 55 Collins Street
MELBOURNE   VIC   3000
Phone: +613.96396036
Site: www.mesoblast.com/

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

SPONSORED STORIES